Quarterly Sales
![AbbVie writes off $2.1B for Imbruvica amid CMS pricing pressure](https://pharmtales.com/wp-content/uploads/2023/10/AbbVie-writes-off-2.1B-for-Imbruvica-amid-CMS-pricing-pressure.jpg)
AbbVie writes off $2.1B for Imbruvica amid CMS pricing pressure
Anika Sharma
The introduction of BeiGene’s groundbreaking oral treatment, Brukinsa, has taken a toll on the sales of AbbVie and Johnson & ...
The introduction of BeiGene’s groundbreaking oral treatment, Brukinsa, has taken a toll on the sales of AbbVie and Johnson & ...